University of Pittsburgh

Other

George Michalopoulos

Joel Byron Nelson

Jianhua Luo

Chien-Cheng Tseng

Yanping Yu

Yangping Yu

Ying Ding

Zhanghui Chen

Taso Georgas

Terry Beckham, Ii

David Hirsch Perlmutter

Tunde Hidvegi

Shuchang Liu

Chi Song

J Eric Golden

William C Bowen

A method for effective delivery of vitamin B12 to a human being involves positioning a delivery device containing a mixture comprising a form of vitamin B12 and water such that, when activated, the delivery device places at least a portion of the mixture inside of a user's mouth in a form suitable for inhalation, and activating the delivery device while or before the user inhales. The form of vitamin B12 may be cyanocobalamin, methylcobalamin, hydroxocobalamin, and/or adenosylcobalamin. The delivery device may be an aerosolizer, atomizer, vaporizer, or humidifier. The mixture may also include flavorings. Water may be 20% or less of the mixture by volume. The mixture may contain no nicotine, propylene glycol, or diacetyl. A method for vitamin B12 supplementation includes determining that a person has a disorder causing the person to have a reduced ability to process B-vitamins and administering methylcobalamin by inhalation.

Inhalation delivery methods and compositions for vitamin B12

The present invention relates to methods for treating patients having cancer or a premalignant or neoplastic condition. It is based, at least in part, on the discovery that a genome editing technique that specifically targets a fusion gene can induce cell death in a cancer cell other than a prostate cancer cell, e.g., a hepatocellular cancer cell, having the fusion gene. The present invention provides methods for treating cancer patients that include performing a genome editing technique targeting a fusion gene present within one or more cells of a subject to produce an anti-cancer effect.

Methods of treating cells containing fusion genes by genomic targeting

The present invention relates to methods of treating cancer patients carrying one or more specific fusion genes. It is based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity and the use of tyrosine kinase inhibitors targeting MAN2A1-FER in a cancer other than prostate, for example hepatocellular cancer, led to dramatic improvement of survival of animals xenografted with the cancer.

Methods of treating cancers containing fusion genes

A pet training pad includes a central absorbent pad on top of a waterproof bottom layer. The waterproof bottom layer covers one side of the central absorbent pad. The pet training pad also includes a wicking material around a periphery of the central absorbent pad and/or one or more fringe barriers around a periphery of the central absorbent pad. A pet training pad manufacturing method involves cutting a bottom waterproof plastic layer, placing die-cut absorbent layers on the bottom plastic layer and laminating or adhering the absorbent layers to the bottom waterproof plastic layer to keep the absorbent layers together and positioned, layering roll cut first fringe borders and wicking edges on the bottom waterproof plastic layer around borders of the absorbent layers and securing them in place, and cutting to create a final shape.

Spill-resistant pet training pad

A method for effective delivery of vitamin B12 to a human being involves positioning a delivery device containing a mixture comprising a form of vitamin B12 and water such that, when activated, the delivery device places at least a portion of the mixture inside of a users mouth in a form suitable for inhalation, and activating the delivery device while or before the user inhales. The form of vitamin B12 may be cyanocobalamin, methylcobalamin, hydroxocobalamin, and/or adenosylcobalamin. The delivery device may be an aerosolizer, atomizer, vaporizer, or humidifier. The mixture may also include flavorings. Water may be 20% or less of the mixture by volume. The mixture may contain no nicotine, propylene glycol, or diacetyl. A method for vitamin B12 supplementation includes determining that a person has a disorder causing the person to have a reduced ability to process B-vitamins and administering methylcobalamin by inhalation.

The present invention relates to methods for determining whether a subject having prostate cancer is at an increased risk for relapse or rapid relapse. It is based, at least in part, on the results of a comprehensive genome analysis of 273 prostate cancer samples, which indicate that the percentage of large size CNVs predicts prostate cancer relapse. In certain embodiments, a method for determining whether a prostate cancer patient has an increased risk of suffering a relapse or a rapid relapse comprises determining the number and size of CNVs in a sample and determining a large size ratio, where if the large size ratio exceeds a particular threshold, the patient is deemed to be at an increased risk for relapse or rapid relapse.

Methods for predicting prostate cancer relapse

The present invention relates to methods and compositions for determining whether a subject having prostate cancer is at greater risk of developing progressive disease, and methods of treating the subjects. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-C5orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of 'progressive prostate cancer'), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that no patient studied survived five years without recurrence if their primary prostate cancer contained a TRMT11-GRIK2 or MTOR-TP53BP1 fusion gene. It is also based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity.

Fusion genes associated with progressive prostate cancer

A sanitary wipe is provided, including a pad that is contained beneath or as part of an adhesive sticker or otherwise attachable body that is releasably secured at any convenient point on a surface of a container or containment vessel, such as the side or top of the containment vessel. The pad can be provided with or without a cleaning substance. For use, the user simply pulls the adhesive sticker or attachable body free of the container, and uses the wipe part or pad of the sticker or body to clean and remove contamination wherever contamination is suspected or at any other desired location, like on the lid of the containment vessel.

Drink container sanitary wipe attachable to a drink container

A portable container base for use with a powered lifting device is provided. The portable container base includes a main body to secure a bottom surface of a container such as a trash can, a plurality of wheels on a lower surface of the main body, each providing independent rotation for moving the main body and container across a surface, and a loading tube on a lower surface of the main body to slidably receive a loading spike of a lifting device, transfer a lifting force from the loading spike to the main body for lifting the container, and restrict movement of the main body around the loading spike during lifting by an interference fit between a circumferential shape of the loading tube and the loading spike, such that a drive mechanism can lift and tilt the container to easily transfer contents from the lifted container to a receiving container.

Portable container base for powered lifting device

The present invention relates to methods for treating prostate cancer patients. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-C5orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of 'progressive prostate cancer'), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that a genome editing technique that specifically targets a fusion gene can induce cell death in a cancer cell that carries the fusion gene.

Methods for treating cells containing fusion genes

The present invention relates to methods and compositions for diagnosing prostate cancer and/or determining whether a prostate cancer patient is at increased risk of suffering a relapse, or a rapid relapse, of his cancer. It is based, at least in part, on the results of a comprehensive genome analysis on 241 prostate cancer samples (104 prostate cancer, 85 matched bloods, 49 matched benign prostate tissues adjacent to cancer, and 3 cell lines) which indicate that (i) genome copy number variation (CNV) occurred in both cancer and non-cancer tissues, and (ii) CNV predicts prostate cancer progression.

Methods for diagnosing prostate cancer and predicting prostate cancer relapse

The present invention relates to methods and compositions for determining whether a subject having prostate cancer is at greater risk of developing progressive disease, and methods of treating the subjects. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-05orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of 'progressive prostate cancer'), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that no patient studied survived five years without recurrence if their primary prostate cancer contained a TRMT11-GRIK2 or MTOR-TP53BP1 fusion gene. It is also based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity.

A powered, waste container lifting and tilting device is provided with a plurality of braces that can be universally attached to any receiving container, a retractable loading spike and strap that can be universally attached to any trash can, and a drive mechanism that can lift and tilt a trash can to easily transfer contents from the lifted trash can to the receiving container.

Growing community of inventors

Pittsburgh, PA, United States of America

George Michalopoulos